Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 1999

View Archived Issues

Priority review status assigned to Rapamune immunosuppressive therapy

Pediatric use of Maxipime approved by the FDA

Roberts and Yuhan enter distribution agreement for Agrylin in Korea

Alza launches Ditropan XL in the U.S.

GABA-A ligands useful for treating CNS disorders

Tachykinin antagonists claimed by HMR for asthma, cough, bronchitis and pain

New series of NHE inhibitors in development at Synthelabo

Enzon initiates phase III trials of PEG-Intron/Rebetol combination therapy for hepatitis C

Improved salts of ACE inhibitors prepared at NicOx

Bayer describes production and use of 2,9-disubstituted purin-6-ones

Schering discloses new leukotriene antagonists particularly useful as dermatological products

Genetics Kenkyusho and Yamanouchi to continue development of joint venture products separately

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Kirin to restart clinical trials of TPO

Clinical trials for Japanese immunosuppressant begin in Europe

KRH-594, a new angiotensin antagonist, evaluated in animal models of hypertension

Genome Therapeutics achieves milestone in asthma alliance with Schering-Plough

Cantab completes acquisition of drug addiction programs from ImmuLogic

New immunomodulator LK-423 possesses unique pharmacological properties

Boehringer Ingelheim seeks E.U. marketing approval for non-CFC respiratory device

Cephalon's narcolepsy treatment launched in Ireland

Moderate drinking reported to protect against ischemic stroke

Ontogen completes phase I study of MDR-modulating compound

Ontogeny enters diabetes research collaboration with Becton Dickinson

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...